

## References

L-28

1. Babacan A, Kizilaslan C, Gun I, et al. CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics. *Int J Clin Exp Med*. 2014; 7(4):1078-1083.
2. Kaufman P, Bloom K, Burris H, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. *Cancer*. 2014.
3. Ip S, Dahabreh IJ, Chung M, et al. An evidence review of active surveillance in men with localized prostate cancer. Agency for Research and Quality. 2014.
4. Klein E, Cooperberg M, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *European Urology*. 2014; 550-560.
5. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Prostate cancer. Version 1.2015.
6. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions of adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Oncology clinical practice guideline. *J Clin Oncol*. 2016; (34).
7. Chen Y, Qu H, Jian M, et al. High level of serum AFP is an independent negative prognostic factor in gastric cancer. *Int J Biol Markers*. 2015; 30(4): e387-e393.
8. Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: A meta-analysis. *World J Surg Oncol*. 2014; 1-6.
9. Geng B, Liang M, Ye X, et al. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. *Molecular and Clinical Oncology*. 2015;3(1): 232-236.
10. American Cancer Society. Tests for prostate cancer. May 15, 2017.
11. American Urological Association. Clinically localized prostate cancer: American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO)/ Society of Urologic Oncology (SUO) guideline. 2017.
12. National Cancer Institute. Tumor markers. November 4, 2015.
13. National Comprehensive Cancer Network (NCCN). NCCN guidelines for patients. Prostate cancer. Version 1.2016.
14. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically meaningful use of blood tumor markers in oncology. *BioMed Research International*. 2016.
15. Ducreux M, Cuhna A S, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2015vol. 26, supplement 5, pp. v56–v68, 2015; 26(5): 56-28.